The Value of In Vitro Binding as Predictor of In Vivo Results: A Case for [18F]FDDNP PET
Tóm tắt
Caution is warranted when in vitro results of biomarkers labeled with tritium were perfunctorily used to criticize in vivo data and conclusions derived with the same tracers labeled with positron emitters and positron emission tomography (PET). This concept is illustrated herein with the PET utilization of [18F]FDDNP, a biomarker used for in vivo visualization of β-amyloid and tau protein neuroaggregates in humans, later contradicted by in vitro data reported with [3H]FDDNP. In this investigation, we analyze the multiple factors involved in the experimental design of the [3H]FDDNP in vitro study that led to the erroneous interpretation of results. The present work describes full details on the synthesis, characterization, purity, and kinetics of radiolytic stability of [3H]FDDNP. The optimal in vitro conditions for detecting tau and β-amyloid protein aggregates using macroscopic and microscopic autoradiography with both [18F]FDDNP and [3H]FDDNP are also presented. Macroscopic autoradiography determinations were performed with [3H]FDDNP of verified purity using established methods described previously in the literature. The autoradiographic results using phosphate buffered saline (PBS) with less than 1 % EtOH and pure, freshly prepared [3H]FDDNP compared with the earlier reported data using [3H]FDDNP of undetermined purity and PBS in 10 % EtOH demonstrate the critical importance of rigorous experimental design for meaningful in vitro determinations. [18F]FDDNP binding to both amyloid plaques and neurofibrillary tangles was confirmed by amyloid and tau immunohistochemical stains of adjacent tissues. This work illustrates the sensitivity of in vitro techniques to various experimental conditions and underscores that conclusions obtained from translational in vitro to in vivo determinations must always be performed with extreme care to avoid wrong interpretations that can be perpetuated and assumed without further analysis.
Tài liệu tham khảo
Chronback LJ, Meehl PE (1955) Construct validity in psychological tests. Psychol Bull 52:281–302
Cole GB, Keum G, Liu J, Small GW, Satyamurthy N, Kepe V, Barrio JR (2010) Specific estrogen sulfotransferase (SULT1E1) substrates and molecular imaging probe candidates. Proc Natl Acad Sci U S A 107:6222–6227
Thompson PW, Ye L, Morgenstern JL, Sue L, Beach TG, Judd DJ, Shipley NJ, Libri V, Lockhart A (2009) Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer’s disease pathologies. J Neurochem 109:623–630
Lockhart A, Lamb JR, Osredkar T et al (2007) PIB is a non-specific imaging marker of amyloid-beta (Aβ) peptide-related cerebral amyloidosis. Brain 1(30):2607–2615
Ye L, Morgenstern JL, Gee AD, Hong G, Brown J, Lockhart A (2005) Delineation of positron emission tomography imaging agent binding sites on β-amyloid peptide fibrils. J Biol Chem 280:23599–23604
Agdeppa ED, Kepe V, Liu J, Flores-Torres S, Satyamurthy N, Petric A, Cole GM, Small GW, Huang SC, Barrio JR (2001) Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for β-amyloid plaques in Alzheimer’s disease. J Neurosci 21:RC189
Agdeppa ED, Kepe V, Petric A et al (2003) In vivo detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer’s brain using the positron emission tomography molecular imaging probe 2-(1-{6-[(2-[18F]fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene)malononitrile. Neuroscience 117:723–730
Bancroft JD, Stevens A (eds) (1990) Theory and practice of histological techniques, 3rd edn. Churchill Livingstone, Edinburgh
Small GW, Kepe V, Ercoli LM, Siddarth P, Bookheimer SY, Miller KJ, Lavretsky H, Burggren AC, Cole GM, Vinters HV, Thompson PM, Huang SC, Satyamurthy N, Phelps ME, Barrio JR (2006) PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 355:2652–2663
Kepe V, Bordelon Y, Boxer A, Huang SC, Liu J, Thiede FC, Mazziotta JC, Mendez MF, Donoghue N, Small GW, Barrio JR (2013) PET imaging of neuropathology in tauopathies: progressive supranuclear palsy. J Alzheimers Dis 36:145–153
Smid LM, Kepe V, Vinters HV, Bresjanac M, Toyokuni T, Satyamurthy N, Wong KP, Huang SC, Silverman DH, Miller K, Small GW, Barrio JR (2013) Postmortem 3-D brain hemisphere cortical tau and amyloid-β pathology mapping and quantification as a validation method of neuropathology imaging. J Alzheimers Dis 36:261–274
Barrio JR, Small GW, Wong KP, Huang SC, Liu J, Merrill DA, Giza CC, Fitzsimmons RP, Omalu B, Bailes J, Kepe V (2015) In vivo characterization of chronic traumatic encephalopathy (CTE) using [F-18]FDDNP-PET brain imaging. Proc Natl Acad Sci USA 112:E2039–E2047
Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergström M, Savitcheva I, Huang GF, Estrada S, Ausén B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Långström B (2004) Imaging brain amyloid in Alzheimer’s disease with Pittsburgh compound-B. Ann Neurol 55:306–319
Verhoeff NPLG, Wilson AA, Takeshita S, Trop L, Hussey D, Singh K, Kung HF, Kung MP, Houle S (2004) In-vivo imaging of Alzheimer’s disease β-amyloid with [11C]SB-13 PET. Am J Geriatr Psychiatry 12:584–595
Bayly RJ, Evans EA (1966) Stability and storage of compounds labelled with radioisotopes. J Label Compd 2:1–34
Liu J, Kepe V, Žabjek A, Petrič A, Padgett HC, Satyamurthy N, Barrio JR (2007) High-yield, automated radiosynthesis of 2-(1-{6-[(2-[18F]fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene)malononitrile ([18F]FDDNP) ready for animal or human administration. Mol Imaging Biol 9:6–16
Amaral DG (1999) Introduction: what is where in the medial temporal lobe? Hippocampus 9:1–6
Voges R, Heys JR, Moenius T (2009) Preparation of compounds labeled with tritium and Carbon-14. Wiley, Chichester
Tkachenko SE, Karpov NA, Fedoseev VM (2000) Autoradiolysis of labeled organic compounds. Radiochemistry 42:211–227
Waterfield WR, Spanner JA, Stanford FG (1968) Tritium exchange from compounds in dilute aqueous solutions. Nature 218:472–473
Jacobson A, Petrič A, Hogenkamp D et al (1996) 1,1-Dicyano-2-[6-(dimethylamino)naphthalene-2-yl]propene (DDNP): a solvent polarity and viscosity sensitive fluorophore for fluorescence microscopy. J Am Chem Soc 118:5572–5579
Petric A, Johnson SA, Pham HV, Li Y, Ceh S, Golobic A, Agdeppa ED, Timbol G, Liu J, Keum G, Satyamurthy N, Kepe V, Houk KN, Barrio JR (2012) Dicyanovinylnaphthalenes for neuroimaging of amyloids and relationships of electronic structures and geometries to binding affinities. Proc Natl Acad Sci U S A 109:16492–16497
Kung MP, Hou C, Zhuang ZP, Skovronsky D, Kung HF (2004) Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer’s disease. Brain Res 1025:98–105
Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, Holt DP, Meltzer CC, DeKosky ST, Mathis CA (2005) Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh compound-B. J Cereb Blood Flow Metab 25:1528–1547
Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL (1996) Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 16:834–840
Logan J (2000) Graphical analysis of PET data applied to reversible and irreversible tracers. Nucl Med Biol 27:661–670
Shogi-Jadid K, Barrio JR, Kepe V et al (2005) Imaging β-amyloid fibrils in Alzheimer’s disease: a critical analysis through simulation of amyloid fibril polymerization. Nucl Med Biol 32:337–351
Shogi-Jadid K, Barrio JR, Kepe V et al (2006) Exploring a mathematical model for the kinetics of β-amyloid molecular imaging probes through a critical analysis of plaque pathology. Mol Imaging Biol 8:151–162
Xia CF, Arteaga J, Chen G, Gangadharmath U, Gomez LF, Kasi D, Lam C, Liang Q, Liu C, Mocharla VP, Mu F, Sinha A, Su H, Szardenings AK, Walsh JC, Wang E, Yu C, Zhang W, Zhao T, Kolb HC (2013) [18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer’s disease. Alzheimers Dement 9:666–676
Vermeiren C, Mercier J, Viot D, Mairet-Coello G, Hannestad J, Courade JP, Citron M, Gillard M (2015) T807, a reported selective tau tracer, binds with nanomolar affinity to monoamine oxidase a. Alzheimer’s Dement Suppl 11:P283
Mitsis EM, Riggio S, Kostakoglu L, Dickstein DL, Machac J, Delman B, Goldstein M, Jennings D, D’Antonio E, Martin J, Naidich TP, Aloysi A, Fernandez C, Seibyl J, DeKosky ST, Elder GA, Marek K, Gordon W, Hof PR, Sano M, Gandy S (2014) Tauopathy PET and amyloid PET in the diagnosis of chronic traumatic encephalopathies: studies of a retired NFL player and of a man with FTD and a severe head injury. Transl Psychiatry 4:e441
Gandy S, DeKosky ST (2014) [18F]-T807 tauopathy PET imaging in chronic traumatic encephalopathy. F1000 Res 3:229
Barrio JR (2018) The irony of PET tau probe specificity. J Nucl Med 59:115–116
Frey KA, Albin RL (1997) Neuroanatomical methods receptor binding techniques. Current protocols in neuroscience. Wiley, New York, pp 1.4.1–1.4.14
Barrio JR (2004) The molecular basis of disease. In: Phelps ME (ed) PET—molecular imaging and its biological applications. Springer, New York, pp 270–320
Hallberg O, Johansson O (2009) Sleep on the right side—get cancer on the left? Pathophysiology 17:157–160
Hallberg O, Johansson O (2002) Cancer trends during the 20th century. ACNEM 21:1–6
Quinn GE, Shin CH, Maguire MG, Stone RA (1999) Myopia and ambient lighting at night. Nature 399:113–114
Wakefield AJ, Murch SH, Anthony A et al (1998) Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 351:637–641 Retracted in 2010
Agdeppa ED, Kepe V, Shoghi-Jadid K et al (2003) 2-Dialkylamino-6-acylmalononitrile substituted naphthalenes (DDNP analogs): novel diagnostic and therapeutic tools in Alzheimer’s disease. Mol Imaging Biol 5:407–417